NEWS OUT !!

Is there anyone on this board that can tell me why this has all of a sudden come to life?

ORNI news

Oragenics Adds Independent Director, Dr. Alan Dunton, to its Board of Directors
Oragenics (OTCBB:ORNI)
Intraday Stock Chart

Today : Monday 4 April 2011
Click Here for more Oragenics Charts.

Oragenics, Inc. (OTCBB:ORNI) (www.oragenics.com), a biopharmaceutical company, announced today that Dr. Alan Dunton formally joined the Company's Board of Directors on April 1, 2011 as independent director and member of the Company’s Audit Committee.

Dr. Frederick Telling, the Company’s Chairman said, "Dr. Dunton is an excellent addition to our Board. Dr. Dunton brings a significant depth of experience in the pharmaceutical industry that will be invaluable to us as we continue to develop our biotechnology technologies.”

Set forth below is background information for Dr. Dunton.

Dr. Alan W. Dunton, age 56 is the principal owner of Danerius, LLC, a biotechnology consulting company which he founded in 2006. From January 2007 until March 2009, Dr. Dunton served as President and Chief Executive Officer of Panacos Pharmaceuticals, Inc. Since 2005, Dr. Dunton has served as the Non-Executive Chairman of the board of directors of ActivBiotics, Inc., a privately held biopharmaceutical company. Previously, he was the President and Chief Executive Officer of Metaphore Pharmaceuticals, Inc. from 2003 until 2006, when it merged with ActivBiotics. From 2004 until 2005, Dr. Dunton served as a member of the board of directors of Vicuron Pharmaceuticals until it was acquired by Pfizer, Inc. In 2002, Dr. Dunton served as President, Chief Operating Officer and a director of Emisphere Technologies, Inc., a biopharmaceutical company. From 1994 to 2001, Dr. Dunton was a senior executive in various capacities in the Pharmaceuticals Group of Johnson & Johnson. From 1999 to 2001, Dr. Dunton was President and Managing Director of The Janssen Research Foundation, a Johnson & Johnson company. From 1998 to 1999, he served as Group Vice President of Global Clinical Research and Development of Janssen. Prior to joining Janssen, Dr. Dunton was Vice President of Global Clinical Research and Development at the R.W. Johnson Pharmaceutical Research Institute, also a Johnson & Johnson company. Prior to joining Johnson & Johnson, Dr. Dunton held positions in clinical research and development at Syntex Corporation, CIBA-GEIGY Corporation and Hoffmann La Roche Inc. Dr. Dunton is currently serving as a member of the board of directors of Targacept, Inc. (NASDAQ:TRGT), a position which he has held since 2006. Dr. Dunton holds a MD degree from New York University School of Medicine, where he completed his residency in internal medicine. He also was a Fellow in Clinical Pharmacology at the New York Hospital/Cornell University Medical Center.

About Oragenics, Inc.

Oragenics is a biopharmaceutical company focused primarily on oral health products and novel antibiotics. Within oral health, Oragenics is developing its pharmaceutical product candidate, SMaRT Replacement Therapy, and also commercializing its oral probiotic product, ProBiora3. Within antibiotics, Oragenics is developing a pharmaceutical candidate, MU1140-S and intends to use its patented, novel organic chemistry platform to create additional antibiotics for therapeutic use.

I agree stocks, ORNI will catch on and attract bio playahs

only a matter of time before this one goes Diva... GO ORNI

ow yes, and the 13 m/a & 20 m/a getting closer to crossing back over too. Go ORNI

looks like MACD getting ready to flip here..bid is above the last trade to!!

no shares available here..this baby can go BIG!!!! ORNI should be on alot of radars soon!!

Yes can't wait to see what they report in their next Financials which should be soon. Last one was in november

big events ahead for ORNI

$ORNI second Phase 1 clinical trial of SMaRT, which is currently set to begin in the first quarter of 2011 at PRA International’s Lenexa, Kansas, clinical facility.

http://finance.yahoo.com/news/Oragenics-Inc-Announces-a-bw-191407695.html?x=0&.v=1

$ORNI recently Finalizes Agreement for Distribution of Its Oral Care Probiotics to North American Dental Professionals Through Partnership with Patterson Dental



Press Release Source: Oragenics, Inc. On Friday February 11, 2011, 8:33 am EST
TAMPA, Fla.--(BUSINESS WIRE)-- Florida-based biopharmaceutical company Oragenics, Inc. (OTCBB:ORNI.ob - News) (www.oragenics.com) has announced that the company’s oral care probiotics – including EvoraPro®, EvoraPlus® and EvoraKids® – will be available to dental professionals across North America through Patterson Dental.

“Building a relationship with Patterson allows us to vastly expand the distribution of our oral care probiotics to dental practices throughout North America,” said Peter Maroon, Oragenics’ Dental Channel Director. “We are very pleased to be working with such a well-known distributor.”

Patterson Dental Director of Marketing, Merchandise Mike Smurr said, “We are delighted to be offering a novel product such as EvoraPro to our dental practices. This unique and innovative product contains beneficial bacteria that help maintain an optimal balance in the mouth, effectively extending that fresh-from-the-dentist clean feeling.”

http://finance.yahoo.com/news/Oragenics-Inc-Finalizes-bw-670021137.html?x=0&.v=1

$ORNI Oragenics is a biopharmaceutical company focused primarily on oral health products and novel antibiotics. Within oral health, Oragenics is commercializing its oral probiotic product, ProBiora3®, and developing its pharmaceutical product candidate, SMaRT Replacement Therapy™. Within antibiotics, Oragenics is developing a pharmaceutical candidate, MU1140-S™ and intends to use its patented, novel organic DPOLT™ platform to create additional antibiotics for therapeutic use.

We r under-construction..let us know if there's anything you want on the board :) cheers

Good Morning everyone:) come follow us

Building shareholder value through
R&D leadership

ProBiora3 Info
Board of Directors
Frederick W. Telling, Chairman of the Board, Chairman of the Compensation Committee
Dr. Telling served as a Director beginning in June 2010 and became Chairman in February 2011. Dr. Telling retired from Pfizer Inc. in June 2007 after 30 years of service. At Pfizer, Dr. Telling served as its Corporate Vice President and Vice President of Corporate Strategic Planning and Policy since October 1994. Dr. Telling also serves as a director and member of the Compensation Committee and Audit Committee at Cell Therapeutics Inc. (NASDAQ: CTIC), a public company based in Seattle, Washington. Dr. Telling also serves on the boards of various civic and non-profit organizations. Dr. Telling holds a B.A. degree in History and Economics from Hamilton College and a MA degree in Industrial and Labor Relations and a PhD in Economics and Public Policy from Cornell University.

Dr. Telling brings to our Board an extensive array of business and industry experience as well as experience as a director of public companies.


Christine Koski, Director
Ms. Koski served as Chairperson from June 2009 to February 2011 and currently serves as a Director. Ms. Koski also serves as CEO of nMetrics, LLC, a provider of web-based manufacturing system software. Prior to joining nMetrics in September 2006, Ms. Koski founded Koski Consulting Group, Inc. in June 2001 to advise start-up companies in the areas of business strategy and marketing. In addition to her positions at nMetrics and Oragenics, Ms. Koski serves as a director at Sun Hydraulics Corporation (NASDAQ: SNHY), a manufacturer of high performance hydraulic valves and solutions, and Cheltec, Inc., a specialty chemical company. Ms. Koski is a managing partner of the Koski Family Limited Partnership, which beneficially owns a controlling interest in the Company. Ms. Koski is a member of the nonprofit National Association of Corporate Directors. Ms. Koski holds an Executive MBA degree from Southern Methodist University’s Cox School of Business and a B.S. degree in Chemistry from St. Lawrence University. Ms. Koski is the sister of our Director, Robert Koski. Ms. Koski brings to the Board over a decade of experience as an executive officer and as a director of other privately held and public technology-based companies. Through her extensive executive management and board experience, Ms. Koski has developed the leadership, business judgment and consensus-building skills necessary to effectively lead our Board as a non-executive Chairperson. Her strong expertise and background in management and marketing and track record as an accomplished executive have provided her with the business acumen and skills necessary to serve as our Chairperson.


Charles L. Pope, Director and Chairman of the Audit Committee
Mr. Pope has served as a Director since June 2010. Mr. Pope currently serves as the Chief Financial Officer of Palm Bancorp, Inc. since June 2009. From September 2007 through June 2009, Mr. Pope served as the Chief Financial Officer of Aerosonic Inc., a manufacturer of aviation products. Mr. Pope served as the Chief Financial Officer of Reptron Inc., a manufacturer of electronic products, from March 2005 through June 2007. From March 2002 to February 2005, Mr. Pope served as Chief Financial Officer of SRI/Surgical Express, Inc. From February 2001 to March 2002 Mr. Pope served as Chief Financial Officer of Innovaro, Inc. (formerly UTEK Corporation). Prior to this time, Mr. Pope served as a Partner in the Audit and Financial Advisory Consulting Divisions and was a Partner in the Accounting and SEC Directorate at PricewaterhouseCoopers LLP. Mr. Pope serves on the board of directors of Inuvo, Inc. in Clearwater, Florida and Innovaro Inc. in Tampa, Florida, each of which are public companies. Mr. Pope holds a B.S. degree in Economics and Accounting from Auburn University and is a Certified Public Accountant in Florida.

Mr. Pope brings to our Board over three decades of experience in the finance and accounting fields. In addition, Mr. Pope also has experience serving as a director of public companies.


Robert Koski, Director and Chairman of the Nomination Committee
Mr. Koski has served as a Director since June 2009. Mr. Koski has practiced as an attorney with the Koski Firm, a sole proprietorship located in Atlanta, Georgia since 1992, where his practice includes litigation and tax law. Mr. Koski has also served as a partner in the Koski Family Limited Partnership, which beneficially owns a controlling interest in the Company, and as a director of the Koski Family Foundation since December 1996. Mr. Koski holds a B.A. degree in Philosophy and English from Colgate University, a JD from Emory School of Law and an LLM degree in Taxation and Litigation from Emory University. He is also the brother of one of our other Directors, Christine Koski.

Mr. Koski brings to our Board over two decades of experience in the legal field as a practicing attorney. In addition to his legal experience, Mr. Koski’s educational background provides a foundation for leadership and consensus-building.


Dr. Jeffrey D. Hillman, Chief Scientific Officer and Director
Dr. Hillman has served as our Chief Scientific Officer and as a Director since November 1996, and as Chairman of our Board of Directors from November 1996 to December 2004. From 1992 through July 2008, Dr. Hillman was a Professor at the University of Florida College of Dentistry. Dr. Hillman received undergraduate training at the University of Chicago (Phi Beta Kappa), and holds a DMD degree ( cum laude ) from the Harvard School of Dental Medicine and a PhD from Harvard University Medical School. He is the inventor or co-inventor of various Oragenics’ technologies.

Dr. Hillman, our founder and longest serving Board member, brings to our Board an extensive background spanning nearly 30 years in biotechnology research and development and a deep knowledge and understanding of Oragenics’ business, operation and employees.

http://www.oragenics.com/investors/financial-reports

http://www.otcmarkets.com/stock/ORNI/company-info

Share Structure
Market Value1 $19,820,766 a/o Feb 25, 2011
Shares Outstanding 5,663,076 a/o Nov 01, 2010
Float N/A
Authorized Shares N/A
Par Value 0.001
Shareholders
Shareholders of Record 95 a/o Mar 31, 2010
Beneficial Shareholders N/A

Overview
We are a biopharmaceutical company focused primarily on oral health products and novel antibiotics. Within oral health, we are developing our pharmaceutical product candidate, SMaRT Replacement Therapy™, and we are also commercializing our oral probiotic blend, ProBiora3®. Within antibiotics, we are developing our pharmaceutical product candidate, MU1140-S™, and we intend to use our patented, novel organic chemistry platform to create additional antibiotics for therapeutic use.

Our SMaRT Replacement Therapy product candidate is designed to be a painless, one-time, five-minute topical treatment applied to the teeth that has the potential to offer lifelong protection against dental caries, or tooth decay. Our SMaRT Replacement Therapy is based on the creation of a genetically modified strain of bacteria that colonizes in the oral cavity and replaces native bacteria that cause tooth decay. We expect to commence a second Phase 1 clinical trial for SMaRT Replacement Therapy which is scheduled to conclude in 2011. We have also developed and are commercializing a variety of products that contain the active ingredient ProBiora3, a patented blend of oral probiotics that promote fresher breath, whiter teeth and supports overall oral health. We have conducted extensive scientific studies on ProBiora3 in order to market our products under self-affirmed Generally Recognized As Safe status, or GRAS. We sell our ProBiora3 products through multiple distribution channels and our customers include Walgreens, Rite Aid, the Kroger family of stores and Garden of Life, among others.

While developing SMaRT Replacement Therapy, members of our scientific team discovered that the SMaRT bacterial strain produces MU1140, a molecule belonging to the novel class of antibiotics known as lantibiotics. MU1140 has proven active preclinically against Gram positive bacteria responsible for a number of healthcare-associated illnesses. We are in the process of scaling up production of our synthetic form of MU1140, or MU1140-S, and expect to commence preclinical testing and to file an Investigational New Drug, or IND, application with the FDA in 2011. The key technology behind the production of MU1140-S is our Differentially Protected Orthogonal Lanthionine Technology platform, or DPOLT, which is a patented, novel organic chemistry platform that we believe will enable the first ever commercial scale, cost-effective production of any of the 50 known lantibiotics. We intend to use DPOLT to create a pipeline of lantibiotics for therapeutic use. Additionally, we are developing non-core technologies that originated from the discoveries of our scientific team, including LPT3-04, which is a weight loss product, and PCMAT, which is a biomarker discovery platform, both of which we believe could provide significant potential opportunities for us.

We were incorporated in November 1996 and commenced operations in 1999. We consummated our initial public offering in June 2003. We have substantially devoted all of our resources to the commercialization of our ProBiora3 products as well as our discovery efforts comprising research and development, clinical trials for our product candidates, protection of our intellectual property and the general and administrative support of these operations. We have generated limited revenues from grants and ProBiora3 product sales through 2010, and have principally funded our operations through the sale of debt and equity securities, including the exercise of warrants issued in connection with these financing transactions. Prior to 2008 our revenues were derived solely from research grants

Helping create the future of medical science

ProBiora3 Info
PIVIAT™ & PCMAT™ Diagnostics
Background
Our biomarker discovery platform is based on our Proteomics-based Change Mediated Antigen Technology, or PCMAT, and was discovered by members of our scientific team while searching for protein targets associated with the diagnosis of periodontal disease. This technology rapidly identifies proteins that are expressed when a cell undergoes any sort of change. Such proteins are excellent targets for medical diagnostics and therapeutic strategies. PCMAT is able to identify proteins shed from diseased tissues into bodily fluids such as blood, saliva and urine. We believe that PCMAT is faster, more cost-efficient and significantly more sensitive than competing technologies such as differential proteomics and microarrays. In addition, our technology uses the actual diseased host rather than an animal model, so that biomarkers that we discover are more likely to be of high clinical value. We have identified several widespread disease states that we intend to pursue. If we are able to discover protein targets with sufficient degrees of sensitivity and specificity, we intend to license these targets to major pharmaceutical or medical diagnostics companies.

Technical Background
PIVIAT avoids the use of animal models by using serum from patients who have experienced disease caused by the pathogen of interest. By pooling sera from several different patients, one can be assured of finding the widest possible array of antigens produced during different stages of infection. The pooled serum is absorbed with whole cells and cellular extracts prepared from the pathogen grown in vitro. The resulting adsorbed serum contains the subpopulation of antibodies reactive against in vivo induced antigens. This adsorbed serum is used to probe an inducible expression library containing DNA from the pathogen of interest cloned into an appropriate host such as Escherichia coli. Reactive clones contain a DNA fragment from the pathogen that encodes an in vivo antigen. PIVIAT has proven its ability to identify novel targets for a number of infectious agents including Vibrio cholera, Escherichia coli and Pseudomonas aeruginosa. Oragenics is currently working with a collection of PIVIAT identified genes of Mycobacterium tuberculosis that are specifically induced during active infection of human patients. These genes, and expressed proteins, are being validated by preeminent tuberculosis experts to determine their potential usefulness in new diagnostic and vaccine applications.?

The PIVIAT process does not require known function to identify a gene target. Given the state of knowledge, a gene of unknown function that is active only during the process of disease may be the most valuable target of all, particularly from the point of view of developing an intellectual property position.?

PCMAT is more general than PIVIAT and allows the study of situations where the host does not mount an antibody response. Proof-of-principle has been accomplished using Xanthomonas campestris infection of the common bean plant, where Oragenics’ scientists have identified both novel virulence genes of the pathogen and novel resistance genes of the host. Essentially, plant tissue can be harvested and quick frozen or otherwise treated to preserve antigens of the pathogen that are present. At the same time, proteins made by the plant in response to the infection are also preserved. When the tissue is mixed with adjuvant and used to immunize an appropriate host, the immune serum that is obtained can be adsorbed with in vitro grown cells of the pathogen to create a probe for identifying virulence genes of the pathogen. It can also be adsorbed with healthy plant tissue to identify resistance genes of the host.?

Helping create the future of medical science

ProBiora3 Info
LPT3-04™ Weight Loss Agent
Background
LPT3-04 is a naturally occurring compound, which is normally consumed in the human diet in small amounts. In the course of our SMaRT Replacement Therapy research program, we discovered that consumption of significantly larger amounts of LPT3-04 resulted in dose-dependent weight loss in experimental animal models. The mechanism of action appears to be induction of apoptosis, or programmed cell death, specifically in white fat cells. LPT3-04 consumption in the required amounts has been shown to be safe in humans. Anecdotally, weight loss has been observed in human volunteers. Due to the natural sweetness of LPT3-04 and the relatively large amounts of it that need to be consumed on a daily basis to achieve the desired weight loss effect, current product development efforts are focused on incorporating the compound into bars, milkshakes, and other food products.

Regulatory status
We have submitted a patent application for the use of LPT3-04 for weight regulation with the United States Patent and Trademark Office, or U.S. PTO.

welcome to the ORNI board!!!